criteria) As noted, TJA is the only approved definitive therapy for moderate-to-severe symptomatic OA of the hip or knee, yet racial disparities in arthroplasty utilization have persisted for decades The Patient Panel was instrumental in the development of this guideline and provided valuable insight into how best to apply these recommendations in the clinical setting. In particular, the Patient Panel stressed the importance of the shared decisionmaking process when indicating a patient for